140 lines
No EOL
27 KiB
XML
140 lines
No EOL
27 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK574493" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK574493/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Lumateperone - LiverTox - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Lumateperone" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2023/06/05" /><meta name="citation_pmid" content="34648250" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK574493/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Lumateperone" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2023/06/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK574493/" /><meta name="description" content="Lumateperone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia. Lumateperone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury." /><meta name="og:title" content="Lumateperone" /><meta name="og:type" content="book" /><meta name="og:description" content="Lumateperone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia. Lumateperone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK574493/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Lumateperone/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK574493/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C6CCA7D7D5ED10000000000D700BE.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK574493_"><span class="title" itemprop="name">Lumateperone</span></h1><p class="small">Last Update: <span itemprop="dateModified">June 5, 2023</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Lumateperone.OVERVIEW"><h2 id="_Lumateperone_OVERVIEW_">OVERVIEW</h2><div id="Lumateperone.Introduction"><h3>Introduction</h3><p>Lumateperone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia. Lumateperone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.</p></div><div id="Lumateperone.Background"><h3>Background</h3><p>Lumateperone (loo” ma te’ per one) is a second generation antipsychotic agent which appears to act as a serotonin (5-HT)-2A receptor and dopamine type 2 (D2) antagonist and is similar in structure and mechanism of action to paliperidone. It has low affinity for histamine-1 and alpha adrenergic-1 receptors and also is a partial serotonin reuptake inhibitor. Several randomized controlled trials have shown that oral lumateperone improves symptoms of schizophrenia and is comparable in effect to risperidone, but may be better tolerated. Lumateperone was approved for use in the United States in 2019 as treatment of adults with schizophrenia. Indications were subsequently extended to include depressive episodes in patients with bipolar I or II disorders including use as an adjunctive therapy with lithium or valproate. Lumateperone is available as capsules of 10.5, 21 and 42 mg under the brand name Caplyta. The recommended dosage in adults is 42 mg once daily. Common side effects include somnolence, fatigue, nausea, dizziness, dry mouth, nasal congestion, anxiety, restlessness and weight gain. Potential but rare severe adverse reactions (mentioned in most antipsychotic and antidepressant product labels) include excess mortality and cerebral vascular accidents in elderly patients with dementia, suicidal thoughts and behaviors, tardive dyskinesia, major neurologic events, neuroleptic malignant syndrome, orthostatic hypotension, seizures and neutropenia.</p></div><div id="Lumateperone.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In preregistration controlled trials, ALT elevations arose in 2% of patients receiving lumateperone compared to less than 1% of placebo controls. The elevations, however, were usually mild, transient and typically resolved without dose modification or drug discontinuation. In preregistration trials, there were no instances of severe hepatic adverse events, discontinuations because of liver related events or episodes of clinically apparent liver injury with jaundice. Since its approval and more widescale use, there have been no published reports of liver injury with symptoms or jaundice attributed to lumateperone therapy, but clinical experience with its use has been limited.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Lumateperone.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which lumateperone might cause serum ALT elevations or liver injury is not known. Lumateperone is metabolized in the liver by multiple enzymes include CYP 3A4, 2C8 and 1A2 and drug-drug interactions may occur with agents that are strong inhibitors or inducers of hepatic microsomal enzymes.</p></div><div id="Lumateperone.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur on lumateperone therapy are usually self-limited and often do not require dose modification or discontinuation. No instances of acute liver failure, chronic hepatitis or vanishing bile duct syndrome have been attributed to lumateperone. Cross sensitivity to liver related or other hypersensitivity reactions between lumateperone and structurally related antipsychotic agents (such as paliperidone, iloperidone, lurasidone, risperidone and ziprasidone) have not been demonstrated, but may well occur.</p><p>Drug Class: <a href="/books/n/livertox/AntipsychoticAgents/">Antipsychotic Agents</a>, Atypicals</p></div></div><div id="Lumateperone.PRODUCT_INFORMATION"><h2 id="_Lumateperone_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
||
<b>REPRESENTATIVE TRADE NAMES</b>
|
||
</p><p>Lumateperone – Caplyta®</p><p>
|
||
<b>DRUG CLASS</b>
|
||
</p><p>Antipsychotic Agents</p><p>
|
||
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lumateperone" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
||
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Lumateperone.CHEMICAL_FORMULAS_AND_STRUC"><h2 id="_Lumateperone_CHEMICAL_FORMULAS_AND_STRUC_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="Lumateperone.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574493/table/Lumateperone.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Lumateperone.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Lumateperone.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Lumateperone.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Lumateperone.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Lumateperone.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Lumateperone.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lumateperone</td><td headers="hd_h_Lumateperone.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/295371011" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">313368-91-1</a>
|
||
</td><td headers="hd_h_Lumateperone.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C24-H28-F-N3-O</td><td headers="hd_h_Lumateperone.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/295371011" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=295371011" alt="image 295371011 in the ncbi pubchem database" /></a>
|
||
</td></tr><tr><td headers="hd_h_Lumateperone.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Paliperidone</td><td headers="hd_h_Lumateperone.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135072932" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">144598-75-4</a>
|
||
</td><td headers="hd_h_Lumateperone.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C23-H27-F-N4-O3</td><td headers="hd_h_Lumateperone.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135072932" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=135072932" alt="image 135072932 in the ncbi pubchem database" /></a>
|
||
</td></tr></tbody></table></div></div></div><div id="Lumateperone.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Lumateperone_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: June 6, 2023</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Lumateperone.REF.meyer.2018">Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 279-302.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Lumateperone.REF.fda">FDA. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>.accessdata<wbr style="display:inline-block"></wbr>.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>/nda/2019/209500Orig1s000MultidisciplineR.pdf</a>.<div><i>(FDA website with product labels and the multidispline review of lumateperone that supported its approval for use in schizophrenia mentions ALT elevations arose in 2% of patients taking lumateperone vs 1% of controls and that 6 of 595 patients in one study developed ALT elevations above 3 times ULN during therapy, but all were less than 5 times ULN and most were self-limited and none were accompanied by jaundice).</i></div></div></li><li><div class="bk_ref" id="Lumateperone.REF.correll.2020.349">Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. <span><span class="ref-journal">JAMA Psychiatry. </span>2020;<span class="ref-vol">77</span>(4):349–358.</span> [<a href="/pmc/articles/PMC6990963/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6990963</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31913424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31913424</span></a>]<div>
|
||
<i>(Among 450 adults with an acute exacerbation of schizophrenia treated with lumateperone [28 or 42 mg] or placebo once daily for 28 days, symptomatic response rates were higher with lumateperone [36% and 37% than placebo 26%] as were adverse event rates [57% and 65% vs 50%] including somnolence, sedation, fatigue and constipation; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF4">Lumateperone (Caplyta) for schizophrenia. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2020;<span class="ref-vol">62</span>(1603):113–116.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32728011" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32728011</span></a>]<div>
|
||
<i>(Concise review of the mechanism of action, clinical efficacy, safety and cost of lumateperone shortly after its approval for use in the US mentions common side effects of somnolence, nausea, dry mouth and elevations in serum aminotransferases).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF.greenwood.2021.98">Greenwood J, Acharya RB, Marcellus V, Rey JA. Lumateperone: a novel antipsychotic for schizophrenia. <span><span class="ref-journal">Ann Pharmacother. </span>2021;<span class="ref-vol">55</span>(1):98–104.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32590907" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32590907</span></a>]<div>
|
||
<i>(Review of the mechanism of action, clinical efficacy and safety of lumateperone mentions that it has high affinity for the serotonin 2A receptor, moderate affinity for dopamine 1 receptor, and may also act as a serotonin-reupdate inhibitor; in two short term clinical trials, lumateperone improved both negative and positive symptoms of schizophrenia, but long term results with comparisons to other second generation antipsychotics have not been reported).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF.correll.2021.198">Correll CU, Vanover KE, Davis RE, Chen R, Satlin A, Mates S. Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia. <span><span class="ref-journal">Schizophr Res. </span>2021;<span class="ref-vol">228</span>:198–205.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33453691" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33453691</span></a>]<div>
|
||
<i>(Among 301 adults with stable schizophrenia who were switched from another atypical antipsychotic to lumateperone for 6 weeks, symptom scores were stable while 31% developed a drug related adverse event which were mostly mild-to-moderate somnolence [7%], headache [5%] and dry mouth [5%], and among the severe adverse events [3%], none were liver related; no mention of ALT elevations).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF.dsouza.2021.150">D'Souza I, Durgam S, Satlin A, Davis RE, Kozauer SG, Chen R, Mates S, et al. Lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized clinical trial. <span><span class="ref-journal">CNS Spectrums. </span>2021;<span class="ref-vol">26</span>:150.</span> Not in PubMed. [<a href="https://pubmed.ncbi.nlm.nih.gov/36779257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36779257</span></a>]<div>
|
||
<i>(Abstract only: among 377 adults with bipolar disorders experiencing a manic episode treated with lumateperone [42 mg] vs placebo daily for 6 weeks, remission rates were 51% vs 37% at day 43, and therapy was “generally well tolerated”; no information on ALT levels or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF.kane.2021.244">Kane JM, Durgam S, Satlin A, Vanover KE, Chen R, Davis R, Mates S. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. <span><span class="ref-journal">Int Clin Psychopharmacol. </span>2021;<span class="ref-vol">36</span>:244–250.</span> [<a href="/pmc/articles/PMC8322041/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8322041</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34054112" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34054112</span></a>]<div>
|
||
<i>(Pooled results from 3 randomized, double-blind controlled trials of lumateperone [n=406] vs risperidone [n=255] and placebo [n=411] for 4 or 6 weeks, overall adverse event rates were 66%, 69% and 55% and there were no deaths and no liver related discontinuations or serious adverse events, and while there were minor average increases in ALT, AST and Alk P on lumateperone therapy, there were no instances of liver injury with jaundice).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF.calabrese.2021.1098">Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, Kozauer SG, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. <span><span class="ref-journal">Am J Psychiatry. </span>2021;<span class="ref-vol">178</span>:1098–1106.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34551584" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34551584</span></a>]<div>
|
||
<i>(Among 377 adults with bipolar disorders experiencing a major depressive episode enrolled in a randomized controlled trial for 6 weeks, symptom scores improved more with lumateperone [42 mg daily] than placebo and adverse events arose in 55% vs 50%, but there were no serious hepatic adverse events; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF10">Lumateperone (Caplyta) for bipolar depression. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2022;<span class="ref-vol">64</span>(1656):126–128.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35921078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35921078</span></a>]<div>
|
||
<i>(Concise review of the mechanism of action, clinical efficacy, safety, and cost of lumateperone shortly after its approval in the US for treatment of bipolar depression; does not mention ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Lumateperone.REF.suppes.2023">Suppes T, Durgam S, Kozauer SG, Chen R, Lakkis HD, Davis RE, Satlin A, et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial. <span><span class="ref-journal">Bipolar Disord. </span>2023 Feb 13;</span> In Press. [<a href="https://pubmed.ncbi.nlm.nih.gov/36779257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36779257</span></a>]<div>
|
||
<i>(Among 529 adults with bipolar I and II disorder on valproate or lithium to which was added lumateperone [28 or 42 mg] or placebo once daily for 6 weeks, depression symptom scores improved more with lumateperone than placebo [-16.2 and -16.9 vs -14.5], while total adverse event rates were similar and side effects more frequent with lumateperone included somnolence, dizziness and nausea; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK574493</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34648250" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">34648250</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Lumasiran/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Lurasidone/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK574493&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK574493/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |